Katamaran Capital LLP Has $1.22 Million Stock Position in Insulet Corporation $PODD

Key Points

• Katamaran Capital LLP significantly cut its stake in Insulet Corporation (PODD) by 66.4%, bringing its holdings to 3,881 shares worth approximately $1.22 million, making it the fund's 24th largest position.
• Insulet's stock has shown resilience, recently reporting earnings per share of $1.17 for the last quarter, surpassing analysts' expectations of $0.92, with a 32.9% year-over-year revenue increase.
• Recent insider trading by senior vice presidents Laetitia Cousin and Prem Singh involved selling shares on September 8th, which reduced their respective holdings by 17.00% and 16.58%.

Katamaran Capital LLP reduced its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 66.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,881 shares of the medical instruments supplier's stock after selling 7,654 shares during the quarter. Insulet accounts for about 1.1% of Katamaran Capital LLP's holdings, making the stock its 24th biggest position. Katamaran Capital LLP's holdings in Insulet were worth $1,219,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Zions Bancorporation National Association UT acquired a new position in shares of Insulet during the first quarter valued at about $26,000. Larson Financial Group LLC grew its holdings in shares of Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock valued at $26,000 after buying an additional 81 shares during the last quarter. SouthState Corp grew its holdings in shares of Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock valued at $28,000 after buying an additional 76 shares during the last quarter. Kozak & Associates Inc. acquired a new position in shares of Insulet during the second quarter valued at about $32,000. Finally, Ramirez Asset Management Inc. acquired a new position in shares of Insulet during the first quarter valued at about $53,000.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president owned 3,890 shares of the company's stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Prem Singh sold 687 shares of the business's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares in the company, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Insulet Stock Up 1.5%

PODD opened at $320.38 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The stock has a market cap of $22.55 billion, a price-to-earnings ratio of 97.38, a PEG ratio of 2.62 and a beta of 1.40. Insulet Corporation has a twelve month low of $226.50 and a twelve month high of $353.50. The company's 50-day moving average price is $323.15 and its two-hundred day moving average price is $299.83.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. The firm had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company's quarterly revenue was up 32.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Truist Financial assumed coverage on shares of Insulet in a research report on Monday, June 16th. They set a "buy" rating and a $365.00 price target on the stock. JPMorgan Chase & Co. raised their price target on shares of Insulet from $340.00 to $415.00 and gave the company an "overweight" rating in a research report on Friday, September 12th. Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Morgan Stanley reissued an "overweight" rating on shares of Insulet in a research report on Thursday, August 7th. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $346.83.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.